PMID: 16525634Mar 10, 2006Paper

Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts

International Journal of Oncology
Li LiMichael Schmitt

Abstract

Vaccination with dendritic cells (DCs) as professional antigen presenting cells generated from autologous leukemic blasts might elicit anti-leukemic T cell responses in patients with acute myeloid leukemia (AML). To test this hypothesis, autologous AML-DC were generated under good manufacturing practice (GMP) conditions and injected s.c. into five AML patients up to four times at a biweekly interval. No severe adverse side effects were observed. Three patients remained in a stable condition for 5.5-13 months and two patients died from rapidly progressive AML. Compared to the initial T cell frequency, enzyme linked immunosorbent spot (ELISPOT) assays revealed a significant increase of granzyme B releasing CD8+ T cells specifically recognizing the PRAME derived peptide (ALYVDSLFFL), a leukemia associated antigen expressed by AML blasts. The cytokine levels in the serum of vaccination AML patients as assessed by cytokine bead assay changed over the period of vaccination to an elevated type 1 T helper cell pattern. Interferon gamma production by CD4+ T helper cells increased during vaccination. In summary, we demonstrated that autologous AML-DC vaccination is well tolerated and can result in an enhanced and specific response of cyt...Continue Reading

Citations

Jan 1, 2014·International Journal of Hematology·Toshio Kitawaki
Sep 5, 2014·Cancer Immunology, Immunotherapy : CII·Marion SubkleweIris Bigalke
Apr 27, 2011·Cancer Immunology, Immunotherapy : CII·Evelien L J SmitsBarbara-Ann Guinn
Oct 26, 2010·Transplantation Proceedings·J Rolinski, I Hus
Dec 23, 2008·Seminars in Hematology·Wing Leung
Sep 16, 2008·Best Practice & Research. Clinical Haematology·Caroline Duncan, Huw Roddie
Mar 21, 2007·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Theresia M WestersArjan A van de Loosdrecht
May 31, 2007·Genes, Chromosomes & Cancer·Tino SchenkHans Peter Saluz
Feb 15, 2011·British Journal of Haematology·Daniel A PollyeaBruno C Medeiros
Jun 13, 2012·Cytotherapy·Sébastien AnguilleZwi N Berneman
Jan 19, 2008·Cytotherapy·H EichlerUNKNOWN Biomedical Excellence for Safer Transfusion Collaborative
Apr 25, 2008·Blood Reviews·Chad M Craig, Gary J Schiller
Jul 29, 2010·Vaccine·Katerina SkalovaJaroslav Michalek
Oct 1, 2008·Hematology/oncology and Stem Cell Therapy·Celso MassumotoLuiz H Camara-Lopes
Mar 31, 2012·Biochemical and Biophysical Research Communications·Sayuri AoyamaShinichiro Takahashi
Aug 22, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Jean-Louis PujolFrédéric F Lehmann
Mar 22, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Barbara-ann GuinnAlbert B Deisseroth
May 1, 2019·Journal of Clinical Medicine·Heleen H Van AckerSébastien Anguille
Mar 18, 2009·The Oncologist·Evelien L J M SmitsViggo F I Van Tendeloo

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.